KEYVIBE-008: what clinicians are saying
MK-7684A in first-line extensive-stage small cell lung cancer · NCT05224141 ↗ · Phase 3 · Merck Sharp & Dohme LLC
KEYVIBE-008 leads a medical oncologist to question whether pembrolizumab could be worse than atezolizumab if TIGIT blockade adds no benefit. A physician doubts that interpretation and relays speculation that toxicity-related discontinuation may have shortened pembrolizumab exposure; neither explanation is demonstrated. Another medical oncologist criticizes the combination for adding toxicity, but these negative assessments do not establish that all anti-TIGIT combinations lack benefit.
Created with AI · how we check it
- edition 2
- commentary checked Nov 15, 2026
- 83 verified statements
This edition $750, with MCP access for your AI agent. Get this report
10 findings, and what sits behind each
01. Clinicians debate whether pembrolizumab itself explains the combination's outcome
3 of the report's 11 cited clinicians · 6 statements from 3 speakers in 2 sources · 7 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Overall Survival (OS), Safety and tolerability, The comparison.
02. Clinicians read KEYVIBE-008 as an unsuccessful combination with added toxicity
4 of the report's 11 cited clinicians · 14 statements from 7 speakers in 9 sources · 13 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Overall Survival (OS), Safety and tolerability, Secondary endpoints.
03. One X account questions the comparator logic; one clinician questions the supporting evidence
2 of the report's 11 cited clinicians · 8 statements from 4 speakers in 4 sources, 1 of them a podcast or video · 8 passages
Limitations recorded: 3.
Draws on: Design and conduct, The comparison.
04. A trial-network account emphasizes referrals; relayed company statements describe a treatment-transition option
No named clinician · accounts and unnamed speakers · 7 statements from 1 speaker in 5 sources · 5 passages
Limitations recorded: 3.
Draws on: Design and conduct, Population and setting.
05. One clinician, described in the source as an author of the results, values rigorous reporting
1 of the report's 11 cited clinicians · 4 statements from 2 speakers in 4 sources · 4 passages
Limitations recorded: 2.
Draws on: Secondary endpoints, Design and conduct.
06. One X account challenges benign TIGIT safety; another ranks GALAXIES more favorably
No named clinician · accounts and unnamed speakers · 4 statements from 1 speaker in 4 sources · 7 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Primary endpoint: Overall Survival (OS).
07. Clinicians discuss small-cell treatment despite cytopenias, with conditional adjustments and support; one addresses access-dependent immunotherapy timing and disease-related liver dysfunction.
3 of the report's 11 cited clinicians · 9 statements from 3 speakers in 1 source, a podcast or video · 6 passages
Limitations recorded: 3.
Draws on: Population and setting, The comparison.
08. One speaker finds choosing between established first-line regimens difficult
2 of the report's 11 cited clinicians · 8 statements from 2 speakers in 3 sources, 1 of them a podcast or video · 7 passages
Limitations recorded: 3.
Draws on: The comparison, Population and setting.
Beyond the trial population
09. Clinicians ask whether anti-TIGIT enrollment and development should continue
5 of the report's 11 cited clinicians · 7 statements from 5 speakers in 5 sources, 1 of them a podcast or video · 6 passages
Limitations recorded: 3.
10. One speaker asks whether inflamed or YAP1-positive data are ready to justify a phenotype-selected immunotherapy trial
1 of the report's 11 cited clinicians · 12 statements from 1 speaker in 1 source, a podcast or video · 5 passages
Limitations recorded: 4.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 10
3 of the report's 11 cited clinicians
Clinicians debate whether pembrolizumab itself explains the combination's outcome
6 statements from 3 speakers in 2 sources
- 6
- statements
- 7
- passages
- 2
- sources
- 3
- speakers
What the statements areViews 2Questions and uncertainty 2Clinical experience 0Comparisons 0Restated results and context 2Statement-to-passage links (a passage can back several statements)Supporting a statement 7Giving context 2Recorded with the findingLimitations: 3
1 post or article · 1 publication
Draws on: Primary endpoint: Overall Survival (OS), Safety and tolerability, The comparison.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
2 of the 10 findings and 18 of the 83 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (5)
HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival; SCLC, small cell lung cancer.
The full KEYVIBE-008 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
In KEYVIBE-008 for first-line extensive-stage small-cell lung cancer, what do clinicians say could distinguish pembrolizumab efficacy from toxicity-related shortening of pembrolizumab exposure as possible explanations for overall-survival findings with vibostolimab–pembrolizumab plus chemotherapy versus atezolizumab plus chemotherapy?
From finding F1 (6 statements from 3 speakers in 2 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 44commentary sources screened
- 21sources cited by verified statements
- 16named in screened sources
- 16speakers cited in the report
- 12cited speakers with a verified identity
11 cited clinicians, speakers with a confirmed clinical role, of them 11 physicians. By role and specialty:
- 8 physician, Medical oncology
- 3 physician, specialty not confirmed
Also in the sources: 3 organizational or shared accounts, not counted as people.
- 83verified statements, each linked to its source
- 46of them from speakers with a confirmed clinical role
- 10findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 13 sections | Paid |
| Verified statements with short source quotes and links | 83 | Paid |
| Who said each statement: the cited speakers | 16 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 11 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 12 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 21 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
14 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Overall Survival (OS) | 10 | 7 |
| Secondary endpoints | 2 | 2 |
| Population and setting | 8 | 2 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 6 | 3 |
| Safety and tolerability | 10 | 9 |
| Design and conduct | 7 | 6 |
| Whether pembrolizumab or toxicity-related exposure explains the combination's outcome | 4 | 1 |
| Treatment transition, continued access and historical referrals | 5 | 3 |
| Evidence thresholds, enrollment ethics and program-level implications | 15 | 7 |
| Cross-program TIGIT safety interpretations | 3 | 3 |
| Reporting an unsuccessful study and sustaining research | 3 | 3 |
| Routine-care adaptation, supportive care and immunotherapy access | 9 | 1 |
| First-line SCLC alternatives and the rationale for the atezolizumab comparator | 8 | 2 |
| Molecular-subtype selection for first-line immunotherapy | 13 | 2 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
83 verified statements from 21 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 30 statements · 36% | ||||
| YouTube | 30 | 1 | 1 | |
| Posts · 37 statements · 45% | ||||
| X threads | 35 | 15 | 41 | |
| LinkedIn posts | 2 | 1 | 1 | |
| Bluesky threads | 0 | 0 | 1 | |
| Primary sources · 16 statements · 19%cited for context, not screened | ||||
| Registry | 12 | 2 | — | |
| Publications | 4 | 2 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 27 / quarter
- Screened window
- Feb 4, 2022 → Oct 27, 2026
- Cited window
- Mar 30, 2022 → Oct 21, 2026
- Retrieved
- Nov 15, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)
- Registry
- NCT05224141
- Study IDs
- 7684A-008 · MK-7684A-008 (MSD) · KEYVIBE-008 (MSD) · jRCT2021220008 (jRCT) · 2023-503517-30-00 (EU CT) · U1111-1287-4436 (UTN) · 2021-005034-42
- Sponsor
- Merck Sharp & Dohme LLC
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 460 actual
- Registered
- 2022-02-04
- Start
- 2022-03-24 actual
- Primary completion
- 2024-06-04 actual
- Primary endpoint
- Overall Survival (OS)
- Interventions
- 6 registered
More on: Small cell lung cancer
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on long-term survival expectations with first-line chemoimmunotherapy versus chemotherapy in extensive-stage small-cell lung cancer; a view on dual checkpoint blockade as first-line treatment for extensive-stage small cell lung cancer; a view on survival-endpoint limitations when interpreting durable responses to first-line chemoimmunotherapy in extensive-stage small-cell lung cancer; a view on TIGIT inhibition as a treatment strategy in first-line extensive-stage small cell lung cancer.
- 48 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 28 sources about other trials or topics are not included.
- The sources reviewed provide qualitative views, not a representative sample of HCP opinion or a measure of consensus. Reposts and repeated company quotations can amplify one original statement.
Show all 14 known gaps +Fewer −
- Discussion that does not name the trial, uses other terminology or appears outside the reviewed channels may be missing.
- Some named accounts do not have an established clinical role in the sources reviewed. Their statements should not be treated as verified HCP assessments.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The interim combination comparison does not isolate pembrolizumab, vibostolimab or toxicity-related exposure as the cause of the outcome. The proposed explanations remain conditional or speculative.
- Cross-study safety rankings and historical survival comparisons are not head-to-head evidence.
- Historical recruitment communications do not establish current availability. Offering atezolizumab does not establish that a patient received it, and continued study access had specific benefit and access conditions.
- The amended protocol stopped further efficacy and survival follow-up and restricted further patient-reported-outcome analysis. A speaker's description of quality-of-life coverage is not reconciled with the amended registry's reporting restriction.
- The molecular-subtype discussion is exploratory, retrospective and limited to the first-line analyses discussed. It does not establish a validated predictive marker for MK-7684A.
- Product information was incomplete for the co-formulation and saline placebo, so the report does not provide an independent label-status assessment.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 15, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. KEYVIBE-008 (NCT05224141): HCP commentary report. Edition 2, v1.1.0. Accepted Nov 15, 2026. https://www.erudio.com/reports/keyvibe-008-nct05224141
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "KEYVIBE-008" (NCT05224141), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "keyvibe-008-nct05224141". If you cannot make requests, read https://www.erudio.com/reports/keyvibe-008-nct05224141.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05224141", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05224141 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/keyvibe-008-nct05224141.json
curl https://www.erudio.com/reports/keyvibe-008-nct05224141.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "keyvibe-008-nct05224141" })release e1c9f3a60fa52841d657515551a268b516a9d7cc04cdaf5e30a45f108209d725
Questions
How much does the KEYVIBE-008 report cost?
One edition costs $750 (Focused · 83 verified statements · 46 from 11 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the KEYVIBE-008 report cover?
83 statements from 21 sources (1 video, 16 posts, 2 papers, 2 registry records), 46 of them from 11 confirmed clinicians, each linked to its source. Commentary checked Nov 15, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the KEYVIBE-008 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "keyvibe-008-nct05224141" }) previews it and create_order({ "report": "keyvibe-008-nct05224141", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the KEYVIBE-008 report?
Edition 2 (version 1.1.0), accepted Nov 15, 2026 UTC; last checked for new commentary Nov 15, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.